Pub Date : 2025-12-12DOI: 10.1097/ALN.0000000000005803
Michael S Avidan, Jon Cohen, Jessica L Saleska
The poem Cassandra's Curse , accompanied by a brief commentary, explores the psychological and existential terrain of routine medical surveillance through the lens of a patient who is also a physician and has stage IV leiomyosarcoma. Using the medium of poetry, the author hopes to offer clinicians, as well as a broader audience, deeper insight into the dread patients with life-limiting illness repeatedly face, even in relation to apparently mundane procedures, such as computed axial tomography scans.
{"title":"Cassandra's Curse.","authors":"Michael S Avidan, Jon Cohen, Jessica L Saleska","doi":"10.1097/ALN.0000000000005803","DOIUrl":"https://doi.org/10.1097/ALN.0000000000005803","url":null,"abstract":"<p><p>The poem Cassandra's Curse , accompanied by a brief commentary, explores the psychological and existential terrain of routine medical surveillance through the lens of a patient who is also a physician and has stage IV leiomyosarcoma. Using the medium of poetry, the author hopes to offer clinicians, as well as a broader audience, deeper insight into the dread patients with life-limiting illness repeatedly face, even in relation to apparently mundane procedures, such as computed axial tomography scans.</p>","PeriodicalId":7970,"journal":{"name":"Anesthesiology","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-12DOI: 10.1097/ALN.0000000000005803
Michael S Avidan, Jon Cohen, Jessica L Saleska
The poem Cassandra's Curse, accompanied by a brief commentary, explores the psychological and existential terrain of routine medical surveillance through the lens of a patient who is also a physician and has stage IV leiomyosarcoma. Using the medium of poetry, the author hopes to offer clinicians, as well as a broader audience, deeper insight into the dread patients with life-limiting illness repeatedly face, even in relation to apparently mundane procedures, such as computed axial tomography scans.
{"title":"Cassandra's Curse.","authors":"Michael S Avidan, Jon Cohen, Jessica L Saleska","doi":"10.1097/ALN.0000000000005803","DOIUrl":"https://doi.org/10.1097/ALN.0000000000005803","url":null,"abstract":"<p><p>The poem Cassandra's Curse, accompanied by a brief commentary, explores the psychological and existential terrain of routine medical surveillance through the lens of a patient who is also a physician and has stage IV leiomyosarcoma. Using the medium of poetry, the author hopes to offer clinicians, as well as a broader audience, deeper insight into the dread patients with life-limiting illness repeatedly face, even in relation to apparently mundane procedures, such as computed axial tomography scans.</p>","PeriodicalId":7970,"journal":{"name":"Anesthesiology","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1097/aln.0000000000005824
Adam J Milam,Zakaria Sharif,Molly B Kraus,David Warner
{"title":"Suzetrigine for the Treatment of Acute Pain: Comment.","authors":"Adam J Milam,Zakaria Sharif,Molly B Kraus,David Warner","doi":"10.1097/aln.0000000000005824","DOIUrl":"https://doi.org/10.1097/aln.0000000000005824","url":null,"abstract":"","PeriodicalId":7970,"journal":{"name":"Anesthesiology","volume":"120 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1097/aln.0000000000005825
Todd Bertoch,Carmen Bozic,Scott G Weiner
{"title":"Suzetrigine for the Treatment of Acute Pain: Reply.","authors":"Todd Bertoch,Carmen Bozic,Scott G Weiner","doi":"10.1097/aln.0000000000005825","DOIUrl":"https://doi.org/10.1097/aln.0000000000005825","url":null,"abstract":"","PeriodicalId":7970,"journal":{"name":"Anesthesiology","volume":"6 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Suzetrigine for the Treatment of Acute Pain: Comment.","authors":"Bingbing Xiang,Chaoyi Deng,Han Yang,Wensheng Zhang","doi":"10.1097/aln.0000000000005823","DOIUrl":"https://doi.org/10.1097/aln.0000000000005823","url":null,"abstract":"","PeriodicalId":7970,"journal":{"name":"Anesthesiology","volume":"43 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1097/aln.0000000000005894
Simone Jansen,Erik Olofsen,Laurence Moss,Joseph C Grieco,Marc L Lesnick,James C Hackworth,Monique van Velzen,Albert Dahan,Elise Sarton,Geert Jan Groeneveld,Marieke Niesters,Rutger van der Schrier
BACKGROUNDThe novel analgesic cebranopadol targets the nociceptin (NOP) and mu-opioid (MOP) receptor, acting as a novel full dual NOP-MOP-receptor agonist, with possible differences in respiratory effects compared to selective MOP-opioids like oxycodone.METHODSIn this randomized, double-blind, placebo-controlled study, 30 healthy volunteers received oral placebo (n=20), cebranopadol (600 µg, n=20; 800 µg, n=20; or 1000 µg, n=20) or oxycodone (30 mg, n=20; or 60 mg, n=20) on 4 occasions in a partial-crossover design. On each occasion ventilation at an extrapolated isohypercapnic level of 55 mmHg (V̇E55) derived from hypercapnic ventilatory responses and electrical pain tolerance tests were obtained at regular intervals before and for 24 h after drug intake. Mixed model analyses on respiratory endpoints was performed (primary endpoint) as well as an exploratory population pharmacokinetic/pharmacodynamic analyses on respiratory and analgesic endpoints.RESULTSOxygen desaturations (to ∼80%) were observed in 65% of subjects after oxycodone 60 mg versus cebranopadol 1000 µg in 25% of subjects (all occurring in between respiratory or pain testing). A significant main effect and a significant separation of all cebranopadol and oxycodone doses versus placebo (all p<0.0001) was observed with cebranopadol 600 μg producing less respiratory depression than oxycodone 30 mg (p=0.022). Pharmacokinetic/pharmacodynamic analyses showed that respiratory C50 values (drug concentration causing 50% effect) was 0.20±0.54 for cebranopadol versus 36±6 ng/mL for oxycodone. Cebranopadol was more potent than oxycodone in producing analgesia.CONCLUSIONSThe primary endpoint showed separation between the respiratory effects of cebranopadol and oxycodone, with 25% less respiratory depression at equianalgesia, as observed in the pharmacokinetic/pharmacodynamic analysis.
{"title":"Respiratory and antinociceptive effects of NOP-MOP agonist cebranopadol versus full opioid receptor agonist oxycodone: a comparison in healthy volunteers.","authors":"Simone Jansen,Erik Olofsen,Laurence Moss,Joseph C Grieco,Marc L Lesnick,James C Hackworth,Monique van Velzen,Albert Dahan,Elise Sarton,Geert Jan Groeneveld,Marieke Niesters,Rutger van der Schrier","doi":"10.1097/aln.0000000000005894","DOIUrl":"https://doi.org/10.1097/aln.0000000000005894","url":null,"abstract":"BACKGROUNDThe novel analgesic cebranopadol targets the nociceptin (NOP) and mu-opioid (MOP) receptor, acting as a novel full dual NOP-MOP-receptor agonist, with possible differences in respiratory effects compared to selective MOP-opioids like oxycodone.METHODSIn this randomized, double-blind, placebo-controlled study, 30 healthy volunteers received oral placebo (n=20), cebranopadol (600 µg, n=20; 800 µg, n=20; or 1000 µg, n=20) or oxycodone (30 mg, n=20; or 60 mg, n=20) on 4 occasions in a partial-crossover design. On each occasion ventilation at an extrapolated isohypercapnic level of 55 mmHg (V̇E55) derived from hypercapnic ventilatory responses and electrical pain tolerance tests were obtained at regular intervals before and for 24 h after drug intake. Mixed model analyses on respiratory endpoints was performed (primary endpoint) as well as an exploratory population pharmacokinetic/pharmacodynamic analyses on respiratory and analgesic endpoints.RESULTSOxygen desaturations (to ∼80%) were observed in 65% of subjects after oxycodone 60 mg versus cebranopadol 1000 µg in 25% of subjects (all occurring in between respiratory or pain testing). A significant main effect and a significant separation of all cebranopadol and oxycodone doses versus placebo (all p<0.0001) was observed with cebranopadol 600 μg producing less respiratory depression than oxycodone 30 mg (p=0.022). Pharmacokinetic/pharmacodynamic analyses showed that respiratory C50 values (drug concentration causing 50% effect) was 0.20±0.54 for cebranopadol versus 36±6 ng/mL for oxycodone. Cebranopadol was more potent than oxycodone in producing analgesia.CONCLUSIONSThe primary endpoint showed separation between the respiratory effects of cebranopadol and oxycodone, with 25% less respiratory depression at equianalgesia, as observed in the pharmacokinetic/pharmacodynamic analysis.","PeriodicalId":7970,"journal":{"name":"Anesthesiology","volume":"7 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1097/aln.0000000000005822
Ammar Siddiqui,Jeff L Xu,Apolonia E Abramowicz
{"title":"Suzetrigine for the Treatment of Acute Pain: Comment.","authors":"Ammar Siddiqui,Jeff L Xu,Apolonia E Abramowicz","doi":"10.1097/aln.0000000000005822","DOIUrl":"https://doi.org/10.1097/aln.0000000000005822","url":null,"abstract":"","PeriodicalId":7970,"journal":{"name":"Anesthesiology","volume":"111 1","pages":""},"PeriodicalIF":8.8,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145732746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号